***Background.*** HIV treatment outcomes and adverse events (AEs) may vary by gender. STaR is the first study to directly compare the safety and efficacy of the two single-tablet regimens (STRs), rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) and efavirenz (EFV)/FTC/TDF.

***Methods.*** STaR was an open-label, 1:1 randomized, 96-week study in treatment-naïve HIV-1 infected subjects. The primary endpoint was the proportion of subjects with HIV-1 RNA \<50 copies/mL at W48 (12% non-inferiority margin; Snapshot analysis). Post-hoc analyses included safety and efficacy by gender through W96.

***Results.*** for the primary endpoint, RPV/FTC/TDF (n = 394) was non-inferior to EFV/FTC/TDF (n = 392) for HIV RNA \<50 copies/mL (85.8% RPV/FTC/TDF vs 81.6% EFV/FTC/TDF; difference 4.1%, 95% CI \[-1.1%, 9.2%\]) at W48 and also at W96 (77.9% vs 72.4%; difference 5.5%, 95% CI \[-0.6%, 11.5%\]) with p = 0.76 for testing homogeneity of response between males and females at W96.

For important AEs listed in the RPV and EFV prescribing information, rates of nervous system AEs were 27.0% RPV/FTC/TDF vs 48.4% EFV/FTC/TDF in males and 28.6% vs 35.7% in females with dizziness and headache being the most frequently reported; psychiatric AEs were 29.0% vs 50.3% in males and 17.9% vs 32.1% in females with abnormal dreams, anxiety, depression and insomnia being the most reported; and for rash events, 16.1% vs 23.4% in males and 10.7% vs 35.7% in females. Rates of Grade 3-4 TEAEs were 9.6% (35/366) RPV/FTC/TDF vs 16.2% (59/364) EFV/FTC/TDF in males, and 17.9% (5/28) vs 21.4% (6/28) in females. Rates of discontinuation due to AEs were 2.7% (10/366) vs 11.0% (40/364) in males and 7.1% (2/28) vs 10.7% (3/28) in females.

###### 

W96 Virologic Suppression by Gender

            RPV/FTC/TDF       EFV/FTC/TDF       Strata Adjusted Diff (95% CI)
  --------- ----------------- ----------------- -------------------------------
  Males     78.7% (288/366)   73.6% (268/364)   5.1% (-1.1% to 11.3%)
  Females   67.9% (19/28)     57.1% (16/28)     12.0% (-15.5% to 39.5%)

***Conclusion.*** Overall, treatment with RPV/FTC/TDF was non-inferior to EFV/FTC/TDF at W48 and W96. Though the number of females enrolled was small, there was no difference in rates of virologic suppression between genders. In the female subpopulation, there were lower rates of important nervous system, psychiatric, and rash AEs and lower rates of discontinuations due to AEs in the RPV/FTC/TDF arm.
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